培美曲塞或多西他赛治疗老年晚期非小细胞肺癌的疗效观察  

Clinical observation on effects of single second-line drug pemetrexed or docetaxel for treating elderly advanced non-small cell lung cancer

作　　者：周恒根[1] 倪敬中[1] 刘兰芳[1] 程燕[1] 李亚莉[1] 李华年[1] 

机构地区：[1]邳州市人民医院肿瘤科,江苏邳州221300

出　　处：《现代医药卫生》2011年第19期2892-2893,共2页Journal of Modern Medicine & Health

摘　　要：目的:探讨单药二线培美曲塞或多西他赛治疗老年晚期非小细胞肺癌的疗效和不良反应。方法:老年复发晚期非小细胞肺癌患者58例,28例单药培美曲塞化疗:培美曲塞500 mg/m2,第一天静脉滴注,每3周为1周期;30例单药多西他赛化疗:多西他赛40mg/m2,第一、八天静脉滴注,每3周为1周期。结果:培美曲塞组和多西他赛组有效率分别为25.0%、23.3%,中位生存期分为9.8个月、8.1个月,1年生存率分别为19.2%、20.0%。两组差异无统计学意义(P>0.05),两组不良反应均可耐受,培美曲塞组未发生Ⅲ度和Ⅳ度血液学不良反应差异有统计学意义(P<0.05)。结论:老年晚期非小细胞肺癌患者可从二线单药培美曲塞或多西他赛化疗中获益,培美曲塞不良反应轻微。Objective ：To observe the efficacy and adverse reactions of single second-line drug pemetrexed or docetaxel for treating elderly advanced non-small cell lung cancer（NSCLC）.Methods：Fifty-eight elderly patients with advanced NSCLC were divided into two groups. In single pemetrexed group,28 cases received pemetrexed at a dose of 500 mg/m2 by intravenous drip on 1 d,and repeated every 3 weeks. In single docetaxel group, 30 cases were treated with docetaxel at a dose of 40 mg/m^2 by intravenous drip on 1,8 d for 3 weeks as a cycle. Results ：The effective rate in pemetrexed group and docetaxel group was 25.0% and 23.3% respectively ;the medial survival time was 9.8 months and 8.1 months respectively; the 1-year survival rate was 19.2% and 20.0% respectively. In two groups,the adverse reactions were tolerable. There was no grade m or 1V hematological adverse reactions in pemetrexed group.Conclusion：Elderly patients with advanced NSCLC could benefit from single second-line drug pemetrexed or docetaxel chemotherapy. Pemetrexed has milder adverse reactions than docetaxel.

关 键 词：晚期非小细胞肺癌 培美曲塞 多西他赛 老年人 

分 类 号：R73[医药卫生—肿瘤]